SLC25A33

Across TCGA pan-cancer cohorts, SLC25A33 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC25A33 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher SLC25A33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A33 expression acts as an unfavorable survival marker.

THCA, LUSC, and LUAD are the cancer types where SLC25A33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.032	0.950	<.001	48	view →
LUSC	OS	Median	II,III,IV	0.112	0.743	<.001	24	view →
LUAD	OS	Median	All	0.266	0.835	.008	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC25A33–THCA (OS)

Open the THCA breakdown →